Cargando…

Allosteric drug transport mechanism of multidrug transporter AcrB

Gram-negative bacteria maintain an intrinsic resistance mechanism against entry of noxious compounds by utilizing highly efficient efflux pumps. The E. coli AcrAB-TolC drug efflux pump contains the inner membrane H(+)/drug antiporter AcrB comprising three functionally interdependent protomers, cycli...

Descripción completa

Detalles Bibliográficos
Autores principales: Tam, Heng-Keat, Foong, Wuen Ee, Oswald, Christine, Herrmann, Andrea, Zeng, Hui, Pos, Klaas M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8242077/
https://www.ncbi.nlm.nih.gov/pubmed/34188038
http://dx.doi.org/10.1038/s41467-021-24151-3
_version_ 1783715551923666944
author Tam, Heng-Keat
Foong, Wuen Ee
Oswald, Christine
Herrmann, Andrea
Zeng, Hui
Pos, Klaas M.
author_facet Tam, Heng-Keat
Foong, Wuen Ee
Oswald, Christine
Herrmann, Andrea
Zeng, Hui
Pos, Klaas M.
author_sort Tam, Heng-Keat
collection PubMed
description Gram-negative bacteria maintain an intrinsic resistance mechanism against entry of noxious compounds by utilizing highly efficient efflux pumps. The E. coli AcrAB-TolC drug efflux pump contains the inner membrane H(+)/drug antiporter AcrB comprising three functionally interdependent protomers, cycling consecutively through the loose (L), tight (T) and open (O) state during cooperative catalysis. Here, we present 13 X-ray structures of AcrB in intermediate states of the transport cycle. Structure-based mutational analysis combined with drug susceptibility assays indicate that drugs are guided through dedicated transport channels toward the drug binding pockets. A co-structure obtained in the combined presence of erythromycin, linezolid, oxacillin and fusidic acid shows binding of fusidic acid deeply inside the T protomer transmembrane domain. Thiol cross-link substrate protection assays indicate that this transmembrane domain-binding site can also accommodate oxacillin or novobiocin but not erythromycin or linezolid. AcrB-mediated drug transport is suggested to be allosterically modulated in presence of multiple drugs.
format Online
Article
Text
id pubmed-8242077
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-82420772021-07-20 Allosteric drug transport mechanism of multidrug transporter AcrB Tam, Heng-Keat Foong, Wuen Ee Oswald, Christine Herrmann, Andrea Zeng, Hui Pos, Klaas M. Nat Commun Article Gram-negative bacteria maintain an intrinsic resistance mechanism against entry of noxious compounds by utilizing highly efficient efflux pumps. The E. coli AcrAB-TolC drug efflux pump contains the inner membrane H(+)/drug antiporter AcrB comprising three functionally interdependent protomers, cycling consecutively through the loose (L), tight (T) and open (O) state during cooperative catalysis. Here, we present 13 X-ray structures of AcrB in intermediate states of the transport cycle. Structure-based mutational analysis combined with drug susceptibility assays indicate that drugs are guided through dedicated transport channels toward the drug binding pockets. A co-structure obtained in the combined presence of erythromycin, linezolid, oxacillin and fusidic acid shows binding of fusidic acid deeply inside the T protomer transmembrane domain. Thiol cross-link substrate protection assays indicate that this transmembrane domain-binding site can also accommodate oxacillin or novobiocin but not erythromycin or linezolid. AcrB-mediated drug transport is suggested to be allosterically modulated in presence of multiple drugs. Nature Publishing Group UK 2021-06-29 /pmc/articles/PMC8242077/ /pubmed/34188038 http://dx.doi.org/10.1038/s41467-021-24151-3 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Tam, Heng-Keat
Foong, Wuen Ee
Oswald, Christine
Herrmann, Andrea
Zeng, Hui
Pos, Klaas M.
Allosteric drug transport mechanism of multidrug transporter AcrB
title Allosteric drug transport mechanism of multidrug transporter AcrB
title_full Allosteric drug transport mechanism of multidrug transporter AcrB
title_fullStr Allosteric drug transport mechanism of multidrug transporter AcrB
title_full_unstemmed Allosteric drug transport mechanism of multidrug transporter AcrB
title_short Allosteric drug transport mechanism of multidrug transporter AcrB
title_sort allosteric drug transport mechanism of multidrug transporter acrb
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8242077/
https://www.ncbi.nlm.nih.gov/pubmed/34188038
http://dx.doi.org/10.1038/s41467-021-24151-3
work_keys_str_mv AT tamhengkeat allostericdrugtransportmechanismofmultidrugtransporteracrb
AT foongwuenee allostericdrugtransportmechanismofmultidrugtransporteracrb
AT oswaldchristine allostericdrugtransportmechanismofmultidrugtransporteracrb
AT herrmannandrea allostericdrugtransportmechanismofmultidrugtransporteracrb
AT zenghui allostericdrugtransportmechanismofmultidrugtransporteracrb
AT posklaasm allostericdrugtransportmechanismofmultidrugtransporteracrb